Nicotinic Acetylcholine Receptor Subunit Alpha-5 Promotes Radioresistance via Recruiting E2F Activity in Oral Squamous Cell Carcinoma
Radiotherapy is commonly used to treat patients with oral squamous cell carcinoma (OSCC), but a subpopulation of OSCC patients shows a poor response to irradiation treatment. Therefore, identifying a biomarker to predict the effectiveness of radiotherapy in OSCC patients is urgently needed. In silic...
Saved in:
| Published in | Journal of clinical medicine Vol. 8; no. 9; p. 1454 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
MDPI
12.09.2019
|
| Online Access | Get full text |
Cover
Loading…
| Abstract | Radiotherapy is commonly used to treat patients with oral squamous cell carcinoma (OSCC), but a subpopulation of OSCC patients shows a poor response to irradiation treatment. Therefore, identifying a biomarker to predict the effectiveness of radiotherapy in OSCC patients is urgently needed. In silico analysis of public databases revealed that upregulation of CHRNA5, the gene encoding nicotinic acetylcholine receptor subunit alpha-5, is extensively detected in primary tumors compared to normal tissues and predicts poor prognosis in OSCC patients. Moreover, CHRNA5 transcript level was causally associated with the effective dose of irradiation in a panel of OSCC cell lines. Artificial silencing of CHRNA5 expression enhanced, but nicotine reduced, the radiosensitivity of OSCC cells. Gene set enrichment analysis demonstrated that the E2F signaling pathway is highly activated in OSCC tissues with high levels of CHRNA5 and in those derived from patients with cancer recurrence after radiotherapy. CHRNA5 knockdown predominantly suppressed E2F activity and decreased the phosphorylation of the Rb protein; however, nicotine treatment dramatically promoted E2F activity and increased Rb phosphorylation, which was mitigated after CHRNA5 knockdown in OSCC cells. Notably, the signature combining increased mRNA levels of CHRNA5 and the E2F signaling gene set was associated with worse recurrence-free survival probability in OSCC patients recorded to be receiving radiotherapy. Our findings suggest that CHRNA5 is not only a useful biomarker for predicting the effectiveness of radiotherapy but also a druggable target to enhance the cancericidal effect of irradiation on OSCC. |
|---|---|
| AbstractList | Radiotherapy is commonly used to treat patients with oral squamous cell carcinoma (OSCC), but a subpopulation of OSCC patients shows a poor response to irradiation treatment. Therefore, identifying a biomarker to predict the effectiveness of radiotherapy in OSCC patients is urgently needed. In silico analysis of public databases revealed that upregulation of
CHRNA5
, the gene encoding nicotinic acetylcholine receptor subunit alpha-5, is extensively detected in primary tumors compared to normal tissues and predicts poor prognosis in OSCC patients. Moreover,
CHRNA5
transcript level was causally associated with the effective dose of irradiation in a panel of OSCC cell lines. Artificial silencing of
CHRNA5
expression enhanced, but nicotine reduced, the radiosensitivity of OSCC cells. Gene set enrichment analysis demonstrated that the E2F signaling pathway is highly activated in OSCC tissues with high levels of
CHRNA5
and in those derived from patients with cancer recurrence after radiotherapy.
CHRNA5
knockdown predominantly suppressed E2F activity and decreased the phosphorylation of the Rb protein; however, nicotine treatment dramatically promoted E2F activity and increased Rb phosphorylation, which was mitigated after
CHRNA5
knockdown in OSCC cells. Notably, the signature combining increased mRNA levels of
CHRNA5
and the E2F signaling gene set was associated with worse recurrence-free survival probability in OSCC patients recorded to be receiving radiotherapy. Our findings suggest that
CHRNA5
is not only a useful biomarker for predicting the effectiveness of radiotherapy but also a druggable target to enhance the cancericidal effect of irradiation on OSCC. Radiotherapy is commonly used to treat patients with oral squamous cell carcinoma (OSCC), but a subpopulation of OSCC patients shows a poor response to irradiation treatment. Therefore, identifying a biomarker to predict the effectiveness of radiotherapy in OSCC patients is urgently needed. In silico analysis of public databases revealed that upregulation of CHRNA5, the gene encoding nicotinic acetylcholine receptor subunit alpha-5, is extensively detected in primary tumors compared to normal tissues and predicts poor prognosis in OSCC patients. Moreover, CHRNA5 transcript level was causally associated with the effective dose of irradiation in a panel of OSCC cell lines. Artificial silencing of CHRNA5 expression enhanced, but nicotine reduced, the radiosensitivity of OSCC cells. Gene set enrichment analysis demonstrated that the E2F signaling pathway is highly activated in OSCC tissues with high levels of CHRNA5 and in those derived from patients with cancer recurrence after radiotherapy. CHRNA5 knockdown predominantly suppressed E2F activity and decreased the phosphorylation of the Rb protein; however, nicotine treatment dramatically promoted E2F activity and increased Rb phosphorylation, which was mitigated after CHRNA5 knockdown in OSCC cells. Notably, the signature combining increased mRNA levels of CHRNA5 and the E2F signaling gene set was associated with worse recurrence-free survival probability in OSCC patients recorded to be receiving radiotherapy. Our findings suggest that CHRNA5 is not only a useful biomarker for predicting the effectiveness of radiotherapy but also a druggable target to enhance the cancericidal effect of irradiation on OSCC. Radiotherapy is commonly used to treat patients with oral squamous cell carcinoma (OSCC), but a subpopulation of OSCC patients shows a poor response to irradiation treatment. Therefore, identifying a biomarker to predict the effectiveness of radiotherapy in OSCC patients is urgently needed. In silico analysis of public databases revealed that upregulation of CHRNA5, the gene encoding nicotinic acetylcholine receptor subunit alpha-5, is extensively detected in primary tumors compared to normal tissues and predicts poor prognosis in OSCC patients. Moreover, CHRNA5 transcript level was causally associated with the effective dose of irradiation in a panel of OSCC cell lines. Artificial silencing of CHRNA5 expression enhanced, but nicotine reduced, the radiosensitivity of OSCC cells. Gene set enrichment analysis demonstrated that the E2F signaling pathway is highly activated in OSCC tissues with high levels of CHRNA5 and in those derived from patients with cancer recurrence after radiotherapy. CHRNA5 knockdown predominantly suppressed E2F activity and decreased the phosphorylation of the Rb protein; however, nicotine treatment dramatically promoted E2F activity and increased Rb phosphorylation, which was mitigated after CHRNA5 knockdown in OSCC cells. Notably, the signature combining increased mRNA levels of CHRNA5 and the E2F signaling gene set was associated with worse recurrence-free survival probability in OSCC patients recorded to be receiving radiotherapy. Our findings suggest that CHRNA5 is not only a useful biomarker for predicting the effectiveness of radiotherapy but also a druggable target to enhance the cancericidal effect of irradiation on OSCC.Radiotherapy is commonly used to treat patients with oral squamous cell carcinoma (OSCC), but a subpopulation of OSCC patients shows a poor response to irradiation treatment. Therefore, identifying a biomarker to predict the effectiveness of radiotherapy in OSCC patients is urgently needed. In silico analysis of public databases revealed that upregulation of CHRNA5, the gene encoding nicotinic acetylcholine receptor subunit alpha-5, is extensively detected in primary tumors compared to normal tissues and predicts poor prognosis in OSCC patients. Moreover, CHRNA5 transcript level was causally associated with the effective dose of irradiation in a panel of OSCC cell lines. Artificial silencing of CHRNA5 expression enhanced, but nicotine reduced, the radiosensitivity of OSCC cells. Gene set enrichment analysis demonstrated that the E2F signaling pathway is highly activated in OSCC tissues with high levels of CHRNA5 and in those derived from patients with cancer recurrence after radiotherapy. CHRNA5 knockdown predominantly suppressed E2F activity and decreased the phosphorylation of the Rb protein; however, nicotine treatment dramatically promoted E2F activity and increased Rb phosphorylation, which was mitigated after CHRNA5 knockdown in OSCC cells. Notably, the signature combining increased mRNA levels of CHRNA5 and the E2F signaling gene set was associated with worse recurrence-free survival probability in OSCC patients recorded to be receiving radiotherapy. Our findings suggest that CHRNA5 is not only a useful biomarker for predicting the effectiveness of radiotherapy but also a druggable target to enhance the cancericidal effect of irradiation on OSCC. |
| Author | Hsu, Kai-Cheng Lin, Che-Hsuan Lee, Hsun-Hua Lu, Long-Sheng Kuei, Chia-Hao Wang, Jia-Yi Lin, Hui-Yu Chang, Jungshan Lee, Fei-Peng Lin, Yuan-Feng |
| AuthorAffiliation | 5 Department of Neurology, School of Medicine, College of Medicine, TMU, Taipei 11031, Taiwan 8 Department of Breast Surgery and General Surgery, Division of Surgery, Cardinal Tien Hospital, Xindian District, New Taipei City 23148, Taiwan 12 Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, TMU, Taipei 11031, Taiwan 10 Department of Otolaryngology, Shuang-Ho Hospital, TMU, New Taipei City 23561, Taiwan; fplee@tmu.edu.tw 2 Department of Otolaryngology, TMU Hospital, TMU, Taipei 11031, Taiwan 1 Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University (TMU), Taipei 11031, Taiwan; cloudfrank@gmail.com (C.-H.L.); js.chang@tmu.edu.tw (J.C.) 13 Cell Physiology and Molecular Image Research Center, Wan Fang Hospital, TMU, Taipei 11696, Taiwan 4 Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan 3 Graduate Institute of Clinical Medicine, College of Medicine, TMU, Taipei 1103 |
| AuthorAffiliation_xml | – name: 4 Department of Neurology, Shuang Ho Hospital, Taipei Medical University, New Taipei City 23561, Taiwan – name: 2 Department of Otolaryngology, TMU Hospital, TMU, Taipei 11031, Taiwan – name: 13 Cell Physiology and Molecular Image Research Center, Wan Fang Hospital, TMU, Taipei 11696, Taiwan – name: 9 Department of Radiation Oncology, TMU Hospital, TMU, Taipei 11031, Taiwan; lslu@tmu.edu.tw – name: 3 Graduate Institute of Clinical Medicine, College of Medicine, TMU, Taipei 11031, Taiwan; kaorulei@yahoo.com.tw (H.-H.L.); pplay1028@gmail.com (C.-H.K.); candycarol0227@gmail.com (H.-Y.L.) – name: 8 Department of Breast Surgery and General Surgery, Division of Surgery, Cardinal Tien Hospital, Xindian District, New Taipei City 23148, Taiwan – name: 10 Department of Otolaryngology, Shuang-Ho Hospital, TMU, New Taipei City 23561, Taiwan; fplee@tmu.edu.tw – name: 1 Graduate Institute of Medical Sciences, College of Medicine, Taipei Medical University (TMU), Taipei 11031, Taiwan; cloudfrank@gmail.com (C.-H.L.); js.chang@tmu.edu.tw (J.C.) – name: 6 Department of Neurology, Vertigo and Balance Impairment Center, Shuang Ho Hospital, TMU, New Taipei City 23561, Taiwan – name: 12 Graduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, TMU, Taipei 11031, Taiwan – name: 11 Department of Otolaryngology, School of Medicine, College of Medicine, TMU, Taipei 11031, Taiwan – name: 7 Department of Urology, Division of Surgery, Cardinal Tien Hospital, Xindian District, New Taipei City 23148, Taiwan – name: 5 Department of Neurology, School of Medicine, College of Medicine, TMU, Taipei 11031, Taiwan |
| Author_xml | – sequence: 1 givenname: Che-Hsuan surname: Lin fullname: Lin, Che-Hsuan – sequence: 2 givenname: Hsun-Hua orcidid: 0000-0002-1473-4799 surname: Lee fullname: Lee, Hsun-Hua – sequence: 3 givenname: Chia-Hao surname: Kuei fullname: Kuei, Chia-Hao – sequence: 4 givenname: Hui-Yu orcidid: 0000-0003-0197-6075 surname: Lin fullname: Lin, Hui-Yu – sequence: 5 givenname: Long-Sheng surname: Lu fullname: Lu, Long-Sheng – sequence: 6 givenname: Fei-Peng surname: Lee fullname: Lee, Fei-Peng – sequence: 7 givenname: Jungshan surname: Chang fullname: Chang, Jungshan – sequence: 8 givenname: Jia-Yi surname: Wang fullname: Wang, Jia-Yi – sequence: 9 givenname: Kai-Cheng surname: Hsu fullname: Hsu, Kai-Cheng – sequence: 10 givenname: Yuan-Feng orcidid: 0000-0003-4456-0766 surname: Lin fullname: Lin, Yuan-Feng |
| BookMark | eNptkV1rFTEQhoNUbK298RfkUoTVfO1HboTDodVCsdLqdZjNZnum7CanSfbA-QH-b3NosSrOTWbIO8-8w7wmRz54R8hbzj5IqdnHezt3THNVqxfkRLC2rZjs5NEf-TE5S-meleg6JXj7ihxLXqtW8e6E_PyKNmT0aOnKuryf7CZM6B29cdZtc4j0dukXj5mupu0Gqpp-i2EO2SV6AwOG6BKmDN46ukM4dMUFC--OnouLgsy4w7yn6Ol1hInePiwwhyXRtZsmuoZo0YcZ3pCXI0zJnT29p-THxfn39Zfq6vrz5Xp1VdliPFcD463UCgYHioNTYNtR9GOptO56LZVwqu-taMQo2FjrsdEMZDto6Iaa60Gekk-P3O3Sz26wzufiymwjzhD3JgCav388bsxd2Jmm7cpsXgDvngAxPCwuZTNjsmUX8K6sZYTQTVNrxUWRvn-U2hhSim78PYYzczideT5dEbN_xBYzZAwHGzj9r-UXoJafhw |
| CitedBy_id | crossref_primary_10_1016_j_semcancer_2023_03_004 crossref_primary_10_1038_s41420_024_02051_x crossref_primary_10_3389_or_2024_1514004 crossref_primary_10_3390_curroncol29120782 crossref_primary_10_3390_pharmaceutics14020275 crossref_primary_10_3390_cancers12092690 crossref_primary_10_3389_fonc_2021_756096 crossref_primary_10_1186_s13005_021_00258_2 crossref_primary_10_2174_1574892816666210806161312 crossref_primary_10_1002_cam4_6482 crossref_primary_10_1007_s13402_020_00581_x crossref_primary_10_3390_ijms24031992 crossref_primary_10_3389_fimmu_2024_1371831 crossref_primary_10_3390_cancers12051324 crossref_primary_10_1186_s12920_023_01470_6 crossref_primary_10_1002_jcp_29956 |
| Cites_doi | 10.1371/journal.pone.0051862 10.1269/jrr.11051 10.1016/j.oraloncology.2010.03.009 10.1016/j.canlet.2015.07.022 10.1038/onc.2010.256 10.1016/j.ctrv.2013.09.007 10.1016/j.ijom.2007.05.016 10.1158/1078-0432.CCR-07-4538 10.1093/jnci/djv100 10.1155/2011/525976 10.1152/physrev.00015.2008 10.4103/ijc.IJC_325_18 10.1093/jnci/djq541 10.1073/pnas.0506580102 10.1016/j.bbrc.2018.12.154 10.2147/OTT.S194129 10.1016/j.bcp.2007.06.033 10.1002/cmdc.200600207 10.7314/APJCP.2015.16.15.6685 10.1101/326470 10.1371/journal.pone.0051967 10.4317/medoral.18772 10.1038/35077011 10.3390/v7031332 10.2500/ajra.2010.24.3456 |
| ContentType | Journal Article |
| Copyright | 2019 by the authors. 2019 |
| Copyright_xml | – notice: 2019 by the authors. 2019 |
| DBID | AAYXX CITATION 7X8 5PM |
| DOI | 10.3390/jcm8091454 |
| DatabaseName | CrossRef MEDLINE - Academic PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 2077-0383 |
| ExternalDocumentID | PMC6780171 10_3390_jcm8091454 |
| GroupedDBID | 53G 5VS 7X7 8FI 8FJ AADQD AAFWJ AAYXX ABDBF ABUWG ACUHS ADBBV AFKRA AFZYC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR CCPQU CITATION DIK FYUFA HMCUK HYE IAO IHR ITC KQ8 M48 MODMG M~E OK1 PGMZT PHGZM PHGZT PIMPY RPM UKHRP 7X8 PUEGO 5PM |
| ID | FETCH-LOGICAL-c421t-d017394adea41ae4ac7f2bfea4998b9342e4bbc262f20f59f690a37d9a8d519d3 |
| IEDL.DBID | M48 |
| ISSN | 2077-0383 |
| IngestDate | Thu Aug 21 14:06:17 EDT 2025 Sun Aug 24 03:35:51 EDT 2025 Tue Jul 01 04:33:51 EDT 2025 Thu Apr 24 22:55:03 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 9 |
| Language | English |
| License | https://creativecommons.org/licenses/by/4.0 Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c421t-d017394adea41ae4ac7f2bfea4998b9342e4bbc262f20f59f690a37d9a8d519d3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0002-1473-4799 0000-0003-0197-6075 0000-0003-4456-0766 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.3390/jcm8091454 |
| PMID | 31547418 |
| PQID | 2296659412 |
| PQPubID | 23479 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_6780171 proquest_miscellaneous_2296659412 crossref_primary_10_3390_jcm8091454 crossref_citationtrail_10_3390_jcm8091454 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 20190912 |
| PublicationDateYYYYMMDD | 2019-09-12 |
| PublicationDate_xml | – month: 9 year: 2019 text: 20190912 day: 12 |
| PublicationDecade | 2010 |
| PublicationTitle | Journal of clinical medicine |
| PublicationYear | 2019 |
| Publisher | MDPI |
| Publisher_xml | – name: MDPI |
| References | Bagan (ref_1) 2010; 46 Araki (ref_27) 2008; 14 Lloyd (ref_9) 2000; 292 Brejc (ref_5) 2001; 411 Subramanian (ref_15) 2005; 102 Shen (ref_22) 2010; 24 ref_14 Wang (ref_20) 2019; 12 Narayanan (ref_24) 2015; 367 ref_18 Ramqvist (ref_17) 2015; 7 ref_16 Arneric (ref_7) 2007; 74 Xu (ref_23) 2007; 36 Rajesh (ref_13) 2018; 55 Nishioka (ref_21) 2019; 509 Ramalho (ref_25) 2012; 6 Schmitz (ref_3) 2014; 40 Chen (ref_12) 2015; 107 Zhang (ref_26) 2012; 53 Romanelli (ref_10) 2007; 2 Albuquerque (ref_6) 2009; 89 Shimizu (ref_19) 2019; 54 Improgo (ref_8) 2010; 29 Huang (ref_4) 2013; 18 Xu (ref_11) 2015; 16 Lin (ref_2) 2011; 2011 Dasgupta (ref_28) 2011; 103 |
| References_xml | – ident: ref_16 doi: 10.1371/journal.pone.0051862 – volume: 53 start-page: 117 year: 2012 ident: ref_26 article-title: Retinoblastoma 94 enhances radiation treatment of esophageal squamous cell carcinoma in vitro and in vivo publication-title: J. Radiat. Res. doi: 10.1269/jrr.11051 – volume: 6 start-page: 163 year: 2012 ident: ref_25 article-title: Retinoblastoma and p53 protein expression in pre-malignant oral lesions and oral squamous cell carcinoma publication-title: Mol. Med. Rep. – volume: 46 start-page: 414 year: 2010 ident: ref_1 article-title: Oral cancer: Clinical features publication-title: Oral Oncol. doi: 10.1016/j.oraloncology.2010.03.009 – volume: 367 start-page: 162 year: 2015 ident: ref_24 article-title: Integrated genomic analyses identify KDM1A’s role in cell proliferation via modulating E2F signaling activity and associate with poor clinical outcome in oral cancer publication-title: Cancer Lett. doi: 10.1016/j.canlet.2015.07.022 – volume: 29 start-page: 4874 year: 2010 ident: ref_8 article-title: From smoking to lung cancer: The CHRNA5/A3/B4 connection publication-title: Oncogene doi: 10.1038/onc.2010.256 – volume: 40 start-page: 390 year: 2014 ident: ref_3 article-title: Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions publication-title: Cancer Treat. Rev. doi: 10.1016/j.ctrv.2013.09.007 – volume: 36 start-page: 739 year: 2007 ident: ref_23 article-title: Nicotine inhibits apoptosis induced by cisplatin in human oral cancer cells publication-title: Int. J. Oral Maxillofac. Surg. doi: 10.1016/j.ijom.2007.05.016 – volume: 14 start-page: 3514 year: 2008 ident: ref_27 article-title: Retinoblastoma RB94 enhances radiation treatment of head and neck squamous cell carcinoma publication-title: Clin. Cancer Res. doi: 10.1158/1078-0432.CCR-07-4538 – volume: 107 start-page: djv100 year: 2015 ident: ref_12 article-title: CHRNA5 risk variant predicts delayed smoking cessation and earlier lung cancer diagnosis--a meta-analysis publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djv100 – volume: 2011 start-page: 525976 year: 2011 ident: ref_2 article-title: Smoking, alcohol, and betel quid and oral cancer: A prospective cohort study publication-title: J. Oncol. doi: 10.1155/2011/525976 – volume: 89 start-page: 73 year: 2009 ident: ref_6 article-title: Mammalian nicotinic acetylcholine receptors: From structure to function publication-title: Physiol. Rev. doi: 10.1152/physrev.00015.2008 – volume: 55 start-page: 399 year: 2018 ident: ref_13 article-title: Nicotinic acetylcholine receptor gene polymorphism is not associated with tobacco-related oral squamous cell carcinoma publication-title: Indian J. Cancer doi: 10.4103/ijc.IJC_325_18 – volume: 103 start-page: 317 year: 2011 ident: ref_28 article-title: ARRB1-mediated regulation of E2F target genes in nicotine-induced growth of lung tumors publication-title: J. Natl. Cancer Inst. doi: 10.1093/jnci/djq541 – volume: 102 start-page: 15545 year: 2005 ident: ref_15 article-title: Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles publication-title: PNAS doi: 10.1073/pnas.0506580102 – volume: 509 start-page: 514 year: 2019 ident: ref_21 article-title: Nicotine exposure induces the proliferation of oral cancer cells through the alpha7 subunit of the nicotinic acetylcholine receptor publication-title: Biochem. Biophys. Res. Commun. doi: 10.1016/j.bbrc.2018.12.154 – volume: 12 start-page: 3327 year: 2019 ident: ref_20 article-title: Nicotine promotes cervical metastasis of oral cancer by regulating peroxiredoxin 1 and epithelial-mesenchymal transition in mice publication-title: Oncol. Targets Ther. doi: 10.2147/OTT.S194129 – volume: 74 start-page: 1092 year: 2007 ident: ref_7 article-title: Neuronal nicotinic receptors: A perspective on two decades of drug discovery research publication-title: Biochem. Pharmacol. doi: 10.1016/j.bcp.2007.06.033 – volume: 2 start-page: 746 year: 2007 ident: ref_10 article-title: Central nicotinic receptors: Structure, function, ligands, and therapeutic potential publication-title: ChemMedChem doi: 10.1002/cmdc.200600207 – volume: 292 start-page: 461 year: 2000 ident: ref_9 article-title: Neuronal nicotinic acetylcholine receptors as novel drug targets publication-title: J. Pharmacol. Exp. Ther. – volume: 16 start-page: 6685 year: 2015 ident: ref_11 article-title: CHRNA5 rs16969968 Polymorphism Association with Risk of Lung Cancer—Evidence from 17,962 Lung Cancer Cases and 77,216 Control Subjects publication-title: Asian Pac. J. Cancer Prev. doi: 10.7314/APJCP.2015.16.15.6685 – volume: 54 start-page: 283 year: 2019 ident: ref_19 article-title: Nicotine promotes lymph node metastasis and cetuximab resistance in head and neck squamous cell carcinoma publication-title: Int. J. Oncol. – ident: ref_14 doi: 10.1101/326470 – ident: ref_18 doi: 10.1371/journal.pone.0051967 – volume: 18 start-page: e233 year: 2013 ident: ref_4 article-title: Oral cancer: Current role of radiotherapy and chemotherapy publication-title: Med. Oral Patol. Oral Cir. Bucal doi: 10.4317/medoral.18772 – volume: 411 start-page: 269 year: 2001 ident: ref_5 article-title: Crystal structure of an ACh-binding protein reveals the ligand-binding domain of nicotinic receptors publication-title: Nature doi: 10.1038/35077011 – volume: 7 start-page: 1332 year: 2015 ident: ref_17 article-title: Human papillomavirus and tonsillar and base of tongue cancer publication-title: Viruses doi: 10.3390/v7031332 – volume: 24 start-page: e73 year: 2010 ident: ref_22 article-title: Nicotine induces resistance to chemotherapy in nasal epithelial cancer publication-title: Am. J. Rhinol. Allergy doi: 10.2500/ajra.2010.24.3456 |
| SSID | ssj0000884217 |
| Score | 2.1941044 |
| Snippet | Radiotherapy is commonly used to treat patients with oral squamous cell carcinoma (OSCC), but a subpopulation of OSCC patients shows a poor response to... |
| SourceID | pubmedcentral proquest crossref |
| SourceType | Open Access Repository Aggregation Database Enrichment Source Index Database |
| StartPage | 1454 |
| Title | Nicotinic Acetylcholine Receptor Subunit Alpha-5 Promotes Radioresistance via Recruiting E2F Activity in Oral Squamous Cell Carcinoma |
| URI | https://www.proquest.com/docview/2296659412 https://pubmed.ncbi.nlm.nih.gov/PMC6780171 |
| Volume | 8 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3dT9swED_xIU17QcCYVjYqo-2Fh2yJ49TOA0KlaoWQyhBQqW-RYztappBCSafxB_B_c5emQBEPvESK_BHbZ_vuF59_B_Cj46dWmDjzwswERKqtPa0ifIg0UJYoqmqe7uFZ52QkTsfReAUW8TubAbx7E9pRPKnRtPj5__b-CBf8ISFOhOy__pprhWoPP7QK66iRJEUyGDZmfr0jKyV4HXyX-1J6PqKyOVPpq-LLuunZ4Fx2l3yhfwabsNEYjqw7l_QWrLhyGz4Mm6PxT_BAMq3omiPrGlfdF9Q1TGFoGLobRNYM94gZLmDWpeu1XsTOa088d8cutM0nCLvJlMQ5wP7lmkpNZzn5RLM-H2CV8ygTLC_Zb2wdu7ydafprwHquKFiPIhKVk2u9A6NB_6p34jUxFjyDQ1J5FldkGAttnRaBdkIbmfE0wzfEYWkcCu5Emhre4Rn3syjOEE3rUNpYK4vGnw0_w1o5Kd0XYFo6y61yUmE9WEmsfJV2slAa3wUuClpwsBjdxDQE5BQHo0gQiJAkkmdJtOD7U96bOe3Gm7n2F0JKcFXQUYcuHfY94RxhXBSLgLdALknvqTri1V5OKfM_Nb826m9iEdp9Vxu-wke0oWq3s4B_g7VqOnN7aKdUaRtW5Vi2Yf24f3Z-0a6n5CN58O0t |
| linkProvider | Scholars Portal |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Nicotinic+Acetylcholine+Receptor+Subunit+Alpha-5+Promotes+Radioresistance+via+Recruiting+E2F+Activity+in+Oral+Squamous+Cell+Carcinoma&rft.jtitle=Journal+of+clinical+medicine&rft.au=Lin%2C+Che-Hsuan&rft.au=Lee%2C+Hsun-Hua&rft.au=Kuei%2C+Chia-Hao&rft.au=Lin%2C+Hui-Yu&rft.date=2019-09-12&rft.issn=2077-0383&rft.eissn=2077-0383&rft.volume=8&rft.issue=9&rft.spage=1454&rft_id=info:doi/10.3390%2Fjcm8091454&rft.externalDBID=n%2Fa&rft.externalDocID=10_3390_jcm8091454 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2077-0383&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2077-0383&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2077-0383&client=summon |